Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 6—June 2020
Dispatch

Cannabis Use and Fungal Infections in a Commercially Insured Population, United States, 2016

Kaitlin BenedictComments to Author , George R. Thompson, and Brendan R. Jackson
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (K. Benedict, B.R. Jackson); University of California Davis Medical Center, Davis, California, USA (G.R. Thompson III)

Cite This Article

Abstract

Case reports have identified invasive fungal diseases in persons who use cannabis, and fungal contamination of cannabis has been described. In a large health insurance claims database, persons who used cannabis were 3.5 (95% CI 2.6–4.8) times more likely than persons who did not use cannabis to have a fungal infection in 2016.

Cannabis can contain fungal pathogens that cause serious and often fatal infections in persons with immunocompromising conditions, such as cancer, transplant, or infection with HIV (1). In these patients, some reasons for using cannabis include pain and nausea relief and appetite stimulation. The frequency of fungal infections associated with cannabis is unknown but is a growing concern as more states legalize its medicinal and recreational use. We used health insurance claims data from 2016 to evaluate the prevalence of fungal infection diagnosis codes among persons who use cannabis and persons who do not use cannabis and to compare demographic and clinical features between these 2 groups.

The Study

The 2016 IBM MarketScan Research Databases (https://www.ibm.com/products/marketscan-research-databases) include claims from outpatient visits and prescriptions and hospitalizations for >27 million employees, dependents, and retirees throughout the United States. MarketScan represents one of the largest collections of such data in the country and captures patient interactions across the full spectrum of healthcare. We used Treatment Pathways, a web-based platform (https://www.ibm.com/us-en/marketplace/marketscan-treatment-pathways), which enable users to query data for persons whose health insurance plans or employers contribute prescription drug data to MarketScan. Because data are fully deidentified, this analysis was not subject to review by the Centers for Disease Control and Prevention institutional review board.

We studied persons with continuous insurance enrollment in 2016, excluding those with diagnosis codes from the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM), for presumed ocular histoplasmosis syndrome (H32 plus B39.4 or B39.9) assigned at an eye care provider (2). We identified patients with ICD-10-CM codes for mold infections (aspergillosis [B44], mucormycosis [B46]) and certain other fungal infections (blastomycosis [B40], coccidioidomycosis [B38], cryptococcosis [B45], histoplasmosis [B39]) among persons who used cannabis (F12.1, F12.2, F12.9) and persons who did not use cannabis. We further explored differences between ICD-10-CM codes for cannabis abuse or dependence (F12.1 and F12.2) and unspecified cannabis use (i.e., without mention of abuse or dependence) (F12.9). We defined immunocompromised status as HIV (B20, O9872, O9873), solid organ or hematopoietic stem cell transplant (Z94, T86), malignant neoplasms (C00–C80 excluding C44), and hematologic malignancies (C81–C96) and also identified tobacco use (Z27.0 or F17.2). We analyzed categorical variables by using χ2 tests and logistic regression.

Forty (0.08%) of 53,217 persons who used cannabis and 6,294 (0.03%) of 21,559,558 persons who did not use cannabis had a fungal infection (odds ratio [OR] 2.6, 95% CI 1.9–3.5). After adjusting for age and immunocompromised status, the adjusted OR (aOR) was 3.5 (95% CI 2.6–4.8). Specifically, persons who use cannabis were more likely than persons who did not use cannabis to have mold infections (0.03% vs. 0.01%; OR 3.4, 95% CI 2.1–5.3, aOR 4.6, 95% CI 2.9–7.4) and other fungal infections (0.04% vs. 0.02%; OR 2.2, 95% CI 1.4–3.3, aOR 2.9, 95% CI 1.9–4.5).

Among patients with fungal infections, persons who used cannabis were significantly younger than persons who did not use cannabis (median age 41.5 years vs. 56.0 years; p<0.001), more likely to be immunocompromised (43% vs. 21%; p<0.001), more likely to be hospitalized on the fungal infection diagnosis date (40% vs. 13%; p<0.001), and more likely to have tobacco use codes (40% vs. 9%; p<0.001) (Table). Sixty percent (n = 24) of persons who used cannabis and had fungal infections had cannabis abuse or dependence codes, compared with 79% of persons who used cannabis and did not have fungal infections, and 48% (n = 19) of persons who used cannabis and had fungal infections had unspecified cannabis use codes, compared with 29% of persons who used cannabis and did not have fungal infections. Persons who used cannabis and had fungal infections and unspecified cannabis use codes were older (median age 52 years vs. 28 years) and more frequently immunocompromised (63% vs. 25%) than persons who used cannabis and had dependence codes.

Conclusions

In this large commercially insured population in the United States, cannabis use was associated with a higher prevalence of certain fungal infections. Although these infections were uncommon, they can result in substantial illness and even death, particularly in immunocompromised persons.

Several hypotheses could explain our findings. First, on the basis of immunocompromised status and hospitalizations, persons who used cannabis appeared to be sicker than persons who did not use cannabis and were therefore presumably at higher risk for fungal infections in general. Some persons who used cannabis might be using medical cannabis to help manage their underlying conditions. In this analysis, it was not possible to determine the source of infection, although contaminated cannabis has been previously implicated in aspergillosis, mucormycosis, and cryptococcal meningitis (35). We are not aware of any reports of blastomycosis, histoplasmosis, or coccidioidomycosis acquired from contaminated cannabis. However, a small risk likely exists; 1 histoplasmosis outbreak occurred in a cannabis field (6), and fomites, such as hay and vegetables, are involved in rare coccidioidomycosis cases (7). Another possible explanation is that smoking-induced structural and immunological lung damage confers increased susceptibility to infection (8), although the lung effects of cannabis might differ from those of tobacco (9). Confounding by tobacco smoking might be another explanation because tobacco use is typically more common among persons who use cannabis (10). Tobacco can also be contaminated with fungi, possibly to a lesser extent than cannabis (11).

Our results could also reflect medical coding artifacts. In general, cannabis use is likely greatly underrepresented by ICD codes (12), supported by the finding that <0.3% of our study population had cannabis use codes, whereas ≈9% of the US population reported using cannabis in the past month (13). Although ICD-10-CM codes cannot distinguish between medical and recreational cannabis use, the higher frequency of immunocompromising conditions and older age among persons who use cannabis and persons who used cannabis and had unspecified cannabis use codes suggests medical cannabis use among some of these patients. We were also unable to differentiate smoking cannabis from other modes of use (e.g., ingestion), which is relevant because smoking might lead to greater fungal exposure through inhalation. Injection drug use, which also might be more common among persons who use cannabis, is an emerging risk factor for some fungal infections, such as invasive candidiasis, although this mode of acquisition seems less likely for the fungal infections described here, which are typically acquired through inhalation. Another limitation is that we did not evaluate immunocompromised status associated with medications such as corticosteroids and tumor necrosis factor inhibitors.

The similar geographic distribution of fungal infections between persons who use cannabis and persons who did not use cannabis is notable because state laws vary substantially regarding medical and recreational use. There is more legalization overall in the western and northeastern United States.

Despite the limitations inherent in administrative data and our inability to infer causality between cannabis use and fungal infections, our study adds to emerging evidence about this association. This finding is consistent with a recommendation that solid organ transplant recipients avoid smoking cannabis (14). Patients with other immunocompromising conditions should be also aware of the possible link between cannabis smoking and fungal infections and might also consider avoiding this exposure. Physicians should remain aware of the possible link between fungal infections and cannabis use.

Ms. Benedict is an epidemiologist in the Mycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA. Her research interests include the epidemiology and prevention of fungal infections.

Top

References

  1. McHardy  I, Romanelli  A, Harris  LJ, Opp  G, Gaudino  R, Torres  A, et al. Infectious risks associated with medicinal Cannabis: Potential implications for immunocompromised patients? J Infect. 2018;76:5001. DOIPubMed
  2. Benedict  K, Beer  KD, Jackson  BR. Histoplasmosis-related healthcare use, diagnosis, and treatment in a commercially insured population, United States. Clin Infect Dis. 2019;•••:ciz324. DOIPubMed
  3. Remington  TL, Fuller  J, Chiu  I. Chronic necrotizing pulmonary aspergillosis in a patient with diabetes and marijuana use. CMAJ. 2015;187:13058. DOIPubMed
  4. Stone  T, Henkle  J, Prakash  V. Pulmonary mucormycosis associated with medical marijuana use. Respir Med Case Rep. 2019;26:1769. DOIPubMed
  5. Shapiro  BB, Hedrick  R, Vanle  BC, Becker  CA, Nguyen  C, Underhill  DM, et al. Cryptococcal meningitis in a daily cannabis smoker without evidence of immunodeficiency. BMJ Case Rep. 2018;2018:bcr-2017221435. DOIPubMed
  6. Ramírez  J. Acute pulmonary histoplasmosis: newly recognized hazard of marijuana plant hunters. Am J Med. 1990;88:60N2N.PubMed
  7. Albert  BL, Sellers  TF Jr. Coccidioidomycosis from fomites. Report of a case and review of the literature. Arch Intern Med. 1963;112:25361. DOIPubMed
  8. Bagaitkar  J, Demuth  DR, Scott  DA. Tobacco use increases susceptibility to bacterial infection. Tob Induc Dis. 2008;4:12. DOIPubMed
  9. Ribeiro  LI, Ind  PW. Effect of cannabis smoking on lung function and respiratory symptoms: a structured literature review. NPJ Prim Care Respir Med. 2016;26:16071. DOIPubMed
  10. Agrawal  A, Budney  AJ, Lynskey  MT. The co-occurring use and misuse of cannabis and tobacco: a review. Addiction. 2012;107:122133. DOIPubMed
  11. Verweij  PE, Kerremans  JJ, Voss  A, Meis  JF. Fungal contamination of tobacco and marijuana. JAMA. 2000;284:2875. DOIPubMed
  12. Vin-Raviv  N, Akinyemiju  T, Meng  Q, Sakhuja  S, Hayward  R. Marijuana use and inpatient outcomes among hospitalized patients: analysis of the nationwide inpatient sample database. Cancer Med. 2017;6:3209. DOIPubMed
  13. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. HHS Publication No. SMA 17–5044, NSDUH Series H-52. Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2017 [cited 2020 Feb 25]. https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2016/NSDUH-FFR1-2016.htm
  14. Avery  RK, Michaels  MG, Infectious Diseases  AST; AST Infectious Diseases Community of Practice. Strategies for safe living following solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13519. DOIPubMed

Top

Table

Top

Cite This Article

DOI: 10.3201/eid2606.191570

Table of Contents – Volume 26, Number 6—June 2020

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Kaitlin Benedict, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop H24-9, Atlanta, GA 30329-4027, USA

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: May 19, 2020
Page updated: May 19, 2020
Page reviewed: May 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external